TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 1-year NACEs after DES implantation
Endpoint domain: Mortality/survival
Primary endpoint: ischemic events (cardiac death, myocardial infarction, target vessel revascularization, stent thrombosis)
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement between measured and estimated serum osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of aggressive behavior problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulty experienced during fiberoptic intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total 17-item HAM-D scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive theory of mind
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Emotional theory of mind
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients with an HIV‐1 RNA level of less than 50 copies per milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPD (Cigarettes Per Day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to quit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Need for antiemetic drugs postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients with PaO2/FIO2<200
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of bacteremia after toothbrushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Risk of spinal NTDs
Endpoint domain: Mortality/survival
Primary endpoint: growth acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: induction of puberty (testicular volume increase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Adherence to guideline-recommended surveillance tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained reduction in tumor volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neointima hyperplasia thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uncovered struts percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Luminal late loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of sexual acts protected by female condoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of female condom at least once in the prior 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recovery of TOF to greater than 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total 24-h energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Voice quality changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean overall score for positive perception of patient safety culture
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cholesterol : HDL ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastroduodenal ulcers and erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HbA1c levels at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PF BML volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence rates to guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients with HbA(1c) < 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of discomfort and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dorsiflexion angle measurement precision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise heart rate maintenance in aerobic training zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maternal nocturnal sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: incidence rate of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: VAS scores for patient discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sinonasal Outcome test‐20 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient compliance to postoperative debridement frequency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Itch reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Good to excellent improvements (>50% improvement)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Steady-state AUC(0,24 h) of bambuterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean terminal half-life of terbutaline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraindividual variation in AUC(0,24 h) of terbutaline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of EtG positive patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative screening test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum CCL20 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pro‐C3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pro‐C6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle mass changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Extreme negative evaluations of self and others
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in HbA1c values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2,000-m rowing-ergometer performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Race split times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average power outputs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hard tissue volume lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: error scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primary effectiveness rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tenderness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cortices united
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average peak load on the operated leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of deep selective bile duct cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Interest in participating in cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disease activity reduction (BASDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-rated ICT knowledge improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the course
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24-h area under the curve (AUC) glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overnight AUC glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tcPO2 value at the level of amputation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in consultation skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft success rate
Endpoint domain: Mortality/survival
Primary endpoint: Negative results for G. vaginalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytologic cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal serum alpha-carotene concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant serum alpha-carotene concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breastmilk beta-carotene concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Shear bond strength between PEEK and resin-based luting agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaizey incontinence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-rating scores for satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 96-hour death/MI/RIUR events
Endpoint domain: Mortality/survival
Primary endpoint: 30-day death/MI events
Endpoint domain: Mortality/survival
Primary endpoint: PRBC transfusions
Endpoint domain: Adverse events/effects
Primary endpoint: clinical pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper extremity disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental cortisol rise after ACTH stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hospital admissions for diabetes-related conditions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: VHI average score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Female Sex Function Index (FSFI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative patient movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of DVT
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of distribution of the central compartment (V(C))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life (T(1/2) (γ))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-body clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients experiencing PONV within 24 h after anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Requests for indomethacin to relieve intolerable pain
Endpoint domain: Adverse events/effects
Primary endpoint: Pain intensity during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infarct Size (IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Nasoenteral obstruction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during OPU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in chronic psychophysiologic insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: T6SS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoleak detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aneurysm diameter measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to LER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to PLMA insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety level after premedication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hemodynamic measurement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary pterygium recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative pressure recorded
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total count of gaseous emboli detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of gaseous emboli detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full recovery (patients with no symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypertensive disorders of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean gestational age at diagnosis of hypertensive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of severe disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daytime nap duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: day‐to‐day variability in WASO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proprioception error of dominant leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static balance with eyes opened
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static balance with eyes closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to manipulate auditory-verbal information
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ability to manipulate visual-spatial information
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ability to store visual-spatial information
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean difference in pre and post treatment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mouth width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary oxalate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cognitive symptom exaggeration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving at least 20% reduction in diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Gingivitis levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: intake of weakly cariogenic food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RR of high-density SM/LB colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Microbial outcomes
Primary endpoint: mean reduction loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence risk of NMIBC
Endpoint domain: Mortality/survival
Primary endpoint: Total kidney volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Blood plasma HIV‐RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seminal plasma HIV‐RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Punctate mechanical pain thresholds (MPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate tachycardia after induction
Endpoint domain: Adverse events/effects
Primary endpoint: maximum increase in cutaneous blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in cardiovascular risk markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in thyrotropin (TSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Asthma monitoring visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency department visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported pleasure expectations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: responsiveness to financial reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interference from appetitive words
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean percentage change in hirsutism scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of seizure frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Overall neurotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall systemic toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental anomalies in children born with UCLP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Access to needed analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Medication safety in outpatient settings
Endpoint domain: Adverse events/effects
Primary endpoint: Effort expended by oncology patients and family caregivers
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: High-sensitivity C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental health symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PC20 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: readmission rate
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cost per case of carcinoma detected and treated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Anxiety experienced during aspiration biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: optimal filled canals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: obturation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in tramadol administration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Residual paravalvular leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: culture count value after decontamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical efficacy (symptoms relief)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient compliance to treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total direct cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improved understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall satisfaction with the consultation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: average knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: non-HDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: TG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Change in glutathione reductase (GSSG-Rd) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preventable adverse events rate
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality rate due to adverse events
Endpoint domain: Mortality/survival
Primary endpoint: Ambulatory status grade 1 or 2 at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume at first Intermittent Catheterization (IDC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urge Urinary Incontinence (UUI) status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death/myocardial infarction/stroke
Endpoint domain: Mortality/survival
Primary endpoint: reduction in drug mismatch between drugs prescribed at discharge and taken at home
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge of drug regimen 10‐14 days after discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes